齐拉西酮联合小剂量丙戊酸钠治疗女性难治性精神分裂症疗效分析

目的探讨齐拉西酮联合小剂量丙戊酸钠治疗女性难治性精神分裂症的临床疗效。方法将90例女性难治性精神分裂症患者随机分为两组,每组45例,治疗组给予齐拉西酮联合小剂量丙戊酸钠治疗,对照组给予氯氮平治疗,疗程均为12周。采用阳性和阴性综合征量表(PANSS)及症状量表(TESS)于治疗前及治疗后1、2、4、8、12周末各评定1次。结果从治疗的第2周末起,两组PANSS的T、P、N、G因子分值分别和治疗前比较有显著性差异(P<0.05或0.01),治疗4周后,差异均有非常显著性(P<0.01);在治疗第4周末,两组间PANSS的T、G因子分值差异有非常显著性(P<00.01);在治疗8周末后,两组间PANSS的T、P、N、G因子分值差异有非常显著性(P<00.01);治疗12周后,两组总有效率差异有显著性(P<0.05),且治疗组的不良反应较对照组轻。结论齐拉西酮联合小剂量丙戊酸钠治疗女性难治性精神分裂症临床疗效显著,安全性高,值得在临床上推广使用。

Curative effect of ziprasidone combined with small doses of valproic acid sodium on females with refractory schizophrenia

Objective To study the clinical effect of ziprasidone combined with small doses of valproic acid sodi-um for treating females with refractory schizophrenia. Methods 90 female patients with refractory schizophrenia were randomly divided into the treatment group and the control group, with 45 cases in each group. The treatment group was treated by ziprasidone combined with small doses of valproic acid sodium, while the control group was treated by clozapine only. Both groups were treated for 12 weeks. Evaluations were performed by positive and negative symp-toms rating scale (PANSS) and the symptom scale(TESS) before the treatment and also at the weekends of the 1st, 2nd,4th,8th, 12th week after the treatment, respectively. Results After 2 weeks of treatment, theT, P, N and G scores of the PANSS of both groups were significantly different from those before the treatment( P <0. 05 or 0. 01). And such difference after 4 weeks of the treatment in both groups were much more statistically significant ( P < 0. 01). At the end of the 4th week after treatment, significant differences were found in T and G factor scores between the two groups( P <0. 01). Furthermore,after 8 weeks' treatment, the T,P,N and G factors scores of two groups were significantly different P <0. 01). Finally,after 12 weeks' treatment, the total effective rates of the two groups were significantly different( P <0. 05) ,and the adverse effect of the treatment group was less than that of the control' group. Conclusion The clinical effect of ziprasidone combined with small doses of valproic acid sodium for female re-fractory schizophrenia is positive. It has high security and worth being widely promoted and applied in clinic.